X0202 SCHEDULE 13G/A 0000929638-24-003553 0001583977 XXXXXXXX LIVE 3 Common Shares 04/28/2026 0001827401 BRIGHT MINDS BIOSCIENCES INC. 10919W405 400 N Aberdeen Street Suite 900 Chicago IL 60642 Rule 13d-1(b) Cormorant Asset Management, LP b DE 0 950000 0 950000 950000 N 9.71 IA PN Chen Bihua b X1 0 950000 0 950000 950000 N 9.71 IN HC BRIGHT MINDS BIOSCIENCES INC. 400 N Aberdeen Street, Suite 900, Chicago, Illinois, 60642 Cormorant Asset Management, LP Bihua Chen This statement is filed by (i) Cormorant Asset Management, LP, a Delaware limited partnership, and the investment adviser to certain funds (the "Cormorant Funds"), with respect to the shares directly held by the Cormorant Funds and (ii) Bihua Chen with respect to the shares directly held by the Cormorant Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares reported herein. 200 Clarendon Street, 52nd Floor Boston, MA 02116 Cormorant Asset Management, LP - Delaware Bihua Chen - United States N IA HC 950,000 9.71% 0 950,000 0 950,000 Shares reported herein for Cormorant Asset Management, LP ("Cormorant") represent shares which are beneficially owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as the general partner of the Master Fund. Cormorant serves as the investment manager of the Master Fund. Bihua Chen serves as the managing member of GP, LLC and the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein. The percentages reported herein with respect to the Reporting Persons' holdings are calculated based upon a statement in the Issuer's Management Discussion and Analysis attached as Exhibit 99.2 to the Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on February 13, 2026 that there were 9,787,161 Common Shares outstanding as of February 12, 2026. Y N See Item 4. The Cormorant Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares reported herein. Cormorant Global Healthcare Master Fund, LP, a Cormorant Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the shares Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Joint Filing Agreement by and among the Reporting Persons, incorporated by reference to Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on October 22, 2024 Cormorant Asset Management, LP /s/ Bihua Chen 04/30/2026 Chen Bihua /s/ Bihua Chen 04/30/2026